Oragenics, Inc.

Type: Public
On the web: http://www.oragenics.com
Employees: 15
Employee growth: (21.1%)

Oragenics wants to get the beneficial microflora in your mouth to bloom. The biotechnology company is developing an oral topical treatment that could provide life-long protection from most forms of tooth decay. It is also researching an antibiotic that could kill harmful bacteria in the mouth, such as drug-resistant Staphylococcus. Its ProBiora consumer product, launched under the EvoraPlus brand, uses beneficial bacteria to promote oral and periodontal health. It is also developing a weight-loss product. Oragenics aims to turn from product development to commercialization through alliances and partnerships.

Key numbers for fiscal year ending December, 2011:
Sales: $1.4M
One year growth: 10.4%
Net income: ($7.7)M

Officers:
Chair: Christine L. Koski
President, CEO, and Director: David B. Hirsch
CFO, Secretary, and Treasurer: Brian Bohunicky

Competitors:
Colgate-Palmolive
DENTSPLY
Procter & Gamble